Contractile forces in platelet aggregates under microfluidic shear gradients reflect platelet inhibition and bleeding risk.
Level III
Where this comes from
- Record sourced from PubMed, PMID 30867419.
- Also identified by DOI 10.1038/s41467-019-09150-9 and PMC identifier 6416331.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Platelets contract forcefully after their activation, contributing to the strength and stability of platelet aggregates and fibrin clots during blood coagulation. Viscoelastic approaches can be used to assess platelet-induced clot strengthening, but they require thrombin and fibrin generation and are unable to measure platelet forces directly. Here, we report a rapid, microfluidic approach for measuring the contractile force of platelet aggregates for the detection of platelet dysfunction. We find that platelet forces are significantly reduced when blood samples are treated with inhibitors of myosin, GPIb-IX-V, integrin α<sub>IIb</sub>β<sub>3,</sub> P2Y<sub>12</sub>, or thromboxane generation. Clinically, we find that platelet forces are measurably lower in cardiology patients taking aspirin. We also find that measuring platelet forces can identify Emergency Department trauma patients who subsequently require blood transfusions. Together, these findings indicate that microfluidic quantification of platelet forces may be a rapid and useful approach for monitoring both antiplatelet therapy and traumatic bleeding risk.
Medical subject headings
- Blood Platelets
- Hemorrhage
- Microfluidics
- Platelet Aggregation
- Platelet Aggregation Inhibitors
- Wounds and Injuries